The Experts in Animal Health

printer friendly

Brakke Consulting’s
Animal Health News & Notes for August 28, 2015

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
Brakke Consulting news
Market research
earnings news
Big Heart
J.M. Smucker
other news
Alivira Animal Health
Gallant Custom Labs
IDT Biologika
Lab M Holdings
Lyka Exports
MediVet Biologics
Natura Petz Organics
Pet Healthy Holdings
SEPTEMBER 24–27, 2015

Join us at SWVS 2015 to learn new ways to compete in an evolving world. The veterinary renaissance is upon us and businesses today have a unique opportunity to reinvent themselves, affect change, and provide dynamic customer experiences. Register today at .

> Patterson Companies, Inc. reported results for its fiscal first quarter ended August 1, 2015. Sales for Patterson Animal Health totaled $557 million, up 44% compared to the first quarter of the prior year (48% on a constant currency basis). Sales from recently acquired Animal Health International contributed $172 million during the quarter. Excluding the acquisition, segment sales were up over 3% on a constant currency basis. (Business Wire) 
> The J. M. Smucker Company announced results for the first quarter ended July 31, 2015, of its 2016 fiscal year. The US Retail Pet Foods segment (formerly Big Heart Pet Brands) contributed net sales of $550 million, representing mid-single digit percent growth compared to Big Heart’s results for the first quarter of the prior year, which were reported under previous ownership. (Company press release) 
> Zoetis announced the availability of Fostera PCV MetaStim. The monovalent killed virus vaccine that helps protect against porcine circovirus associated diseases (PCVAD) caused by porcine circovirus Type 2 (PCV2) has been updated with the commonly used adjuvant known as MetaStim (the common name for the SP (squalane, Pluronic) oil adjuvant). (company press release)
> China-based Skystar Bio-Pharmaceutical Company announced that on August 19, 2015, the Company received a notification from the Nasdaq Stock Market informing the Company that because it had not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letters do not result in the immediate delisting of the Company’s common stock, and the stock will continue to trade uninterrupted under its current trading symbol, but the Company’s common stock will be subject to delisting by Nasdaq if the deficiency is not resolved. ( 
> MediVet Biologics announced that it will open a second US laboratory in Manhattan, Kansas in early October, 2015. Recently, MediVet Biologics licensed the Intellectual Property rights to produce an Allogeneic Stem Cell Therapy product, MB-007, from the Kansas State University Research Foundation for potential orthopedic and internal medicine applications for both veterinary and human clinical use. ( 
> Natura Petz Organics announced the launch of eight formulations in an organic supplement line for dogs and cats. The products are formulated as capsules that can be administered whole or opened and sprinkled onto the pet’s food. (Pet Business) 
> Pet Healthy Holdings announced a formative licensing agreement with NoScentNaturals to be the company’s US distributor. Pet Healthy’s Perfect Litter was chosen by NoScentNaturals to be the first US-based manufacturer of cat litter utilizing the No Scent odor elimination technology. (Pet Age) 
> UK  Neogen Corporation announced that it has acquired the stock of United Kingdom-based Lab M Holdings, a developer, manufacturer and supplier of microbiological culture media and diagnostic systems. Financial terms were not disclosed. (company press release) 
> CANADA  IDT Biologika announced the acquisition of Canadian company Gallant Custom Laboratories, the only Canadian company authorized by the Canadian Food Inspection Agency (CFIA) to manufacture autogenous viral and bacterial vaccines. Gallant serves customers throughout Canada, particularly to those who provide vaccines to the Canadian livestock and poultry industry. Financial terms were not disclosed. (sys-con media)
> ITALY  Fatro announced it will develop two veterinary vaccines using Valneva’s EB66 cell line. Under the terms of the agreement, Valneva received an undisclosed upfront payment and is eligible to receive milestone payments as well as future royalties on net sales of Fatro’s vaccines. Italian-based Fatro currently sells its proprietary vaccines for swine influenza, avian influenza, Newcastle disease and Marek’s disease, as well as a host of other diseases in food-producing animals in roughly 90 countries globally. (Animal Pharm)
> INDIA  Alivira Animal Health, a subsidiary of Sequent Scientific, announced it has entered into a definitive agreement with Lyka Exports, a subsidiary of Lyka Labs, under which Alivira will acquire the animal health business of Lyka Exports on a going concern basis. In FY15, Lyka’s animal health business registered a top line of close to Rs 23.50 crore ($3.5 million), and the business is growing by over 30% during the ongoing financial year. Financial terms were not disclosed. (
> BELGIUM – BOVINE TB  Belgian vets have said 19 dairy farms are still under suspicion after an outbreak of bovine tuberculosis (bTB) earlier this month. Belgium was declared officially free of bovine tuberculosis in 2003; however, nine cases surfaced in 2013. Should Belgium lose its bTB-free status, it will be banned from exporting cows to other EU countries. (Animal Pharm)
> GERMANY – ANTIBIOTIC USE  Germany’s use of veterinary antibiotics has declined year-on-year by about 15%. Germany’s Federal Office of Consumer Protection and Food Safety (BVL) reported that there were about 1,238 tons of veterinary antibiotics sold to veterinarians in 2014, a decline of 15% compared to 2013. However, the BVL said the amount of antibiotics with special significance for human therapy remained constant compared to 2013. The use of antibiotics for growth promotion has been banned in Germany since 2006. (Animal Pharm)
Look Before You Leap

Depend on Brakke Consulting to build a market study to meet your company’s needs, whether it is:

• Assessing the feasibility of a new product or technology
• Identifying the opinions and trends of veterinarians, pet owners or producers
• Determining the current market for products

With our in-house database of veterinarians and the ability to custom-tailor surveys of a wide variety of target audiences, we provide reliable insights into this unique industry. We also produce multiclient reports in a number of high-interest animal health market areas. For more information, see our website or call our Dallas office at 972-243-4033.

The news this week covers a number of various product categories. One story covers the purchase of an autogenous vaccine manufacturer and another the out-licensing of an early stage vaccine cell line technology. There are stories related to various organic or natural products of one type or another being licensed or introduced into the pet market. One of the quarterly earnings reports covers another large consolidation in the animal health distribution segment.

If one takes a 30,000-foot view of the trends in the industry it is reasonably clear that attitudes in consumers’ minds towards antibiotics are unfavorable and anything with the words “organic” or “natural” are favorable. Also, prevention is preferred over therapy, and diagnostics of various types will continue to play an increasing role in the health of animals and poultry.

We want to wish all of those companies presenting at the KC Animal Health Investment Forum next week the best of luck in finding the capital needed to move their product or technology forward. Also, congratulations again to Dr. Ralph Richardson in receiving the 2015 KC Animal Health “Iron Paw Award” for his contributions to the animal health industry.

Have a great weekend!!
Ron Brakke

This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX  75234    USA

en_USEnglish (United States)